MGMT and central nervous system cancer: Previous studies on radiological evaluation of the MGMT promoter methylation status have mainly focused on the visual features, quantitative parameters or high-throughput radiomics features [13–15, 31–34] of gliomas (mostly glioblastomas) based on multimodal MRI and have reported accuracies ranging from 0.58–0.89 and AUCs ranging from 0.75–0.92 (without distinguishing training and validation data).